Insider Selling: Beigene, Ltd. (NASDAQ:ONC) Insider Sells 1,402 Shares of Stock

Beigene, Ltd. (NASDAQ:ONC) insider Lai Wang sold 1,402 shares of Beigene stock in a transaction that occurred on Friday, June 6th. The stock was sold at an average price of $252.39, for a total transaction of $353,850.78. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

Beigene Stock Performance

ONC stock opened at $276.53 on Friday. Beigene, Ltd. has a one year low of $141.31 and a one year high of $287.88. The stock has a fifty day moving average of $240.18. The company has a debt-to-equity ratio of 0.05, a current ratio of 1.93 and a quick ratio of 1.72. The stock has a market capitalization of $32.74 billion, a P/E ratio of -33.56, a PEG ratio of 7.73 and a beta of 0.30.

Beigene (NASDAQ:ONC) last released its earnings results on Wednesday, May 7th. The company reported $1.22 EPS for the quarter, topping the consensus estimate of ($0.71) by $1.93. Beigene had a negative net margin of 25.94% and a negative return on equity of 25.12%. The firm had revenue of $1.12 billion for the quarter, compared to the consensus estimate of $1.12 billion. On average, research analysts predict that Beigene, Ltd. will post -5.82 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of brokerages have recently commented on ONC. Royal Bank of Canada reduced their price target on shares of Beigene from $312.00 to $311.00 and set an “outperform” rating for the company in a research note on Thursday, May 8th. JMP Securities set a $348.00 price objective on shares of Beigene in a report on Friday, February 28th. Sanford C. Bernstein set a $259.00 price objective on shares of Beigene in a report on Thursday, March 13th. JPMorgan Chase & Co. raised their price objective on shares of Beigene from $311.00 to $317.00 and gave the stock an “overweight” rating in a report on Monday, April 21st. Finally, Guggenheim raised their price objective on shares of Beigene from $348.00 to $350.00 and gave the stock a “buy” rating in a report on Thursday, May 8th. Seven analysts have rated the stock with a buy rating, According to MarketBeat.com, the company has an average rating of “Buy” and an average target price of $319.00.

Beigene Company Profile

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations.